Abstract 1434P
Background
The spatial architecture of B and T cells in the tumor microenvironment (TME) is known to be associated with treatment response in cancer patients. However, more complex spatial statistics to characterize the interaction of more than two immune cell types could further inform our understanding of tumor response to immunotherapy (IO). In this work we sought to evaluate quantitative metrics of higher order spatial relationships between multiple (>2) cell types to better characterize and predict overall survival (OS) in NSCLC patients.
Methods
The study included quantitative immunofluorescence images of pre-IO tumor biopsy specimen of 135 NSCLC patients from five centers with OS information. To predict OS, a set of 223 image features that characterize the spatial interplay of different cell types (CD4+, CD20+, CD8+, tumor, and stroma) in the TME were extracted. First, every nucleus belonging to each immune cell family was detected using an image analysis program (MATLAB) to identify the cell’s expression, subsequently the cell coordinates were recorded. The algorithm then identifies each triplet of distinct cells in proximity of each other to form spatial triangles. Features relating to the density, neighborhood, and proximity of nuclei were subsequently extracted. A risk score (RS) was then computed for each patient using the least absolute shrinkage and selection operator. To predict OS, the Cox regression model was trained on 100 patients (St) and validated on 35 patients (Sv). The discriminative ability of the features was assessed using Kaplan-Meier and log-rank tests.
Results
The RS was significantly associated with OS in both St (HR: 1.76; 95% CI = 1.09 - 2.85; P = .02), and Sv (HR: 2.8; 95% CI= 1.18–6.68; P=.01). RS based risk stratification showed greater accumulation of tumor, CD4 T cells, and CD20 B cells in very close proximity of each other in low-risk patients, compared to high-risk patients.
Conclusions
Machine learning derived features describing the higher order spatial relationships between tumor, CD20 B cells, and CD4 T cells were found to be associated with OS in NSCLC patients treated with IO. Additional, independent multi-site validation of these findings is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Schalper: Financial Interests, Speaker, Consultant, Advisor: Agenus, Ariagen, AstraZeneca, Bristol Myers Squibb , Clinica Alemana de Santiago, Genmab, Merck Sharp and Dohme, OnCusp Therapeutics, Repertoir Therapeutics, Takeda Oncology; Financial Interests, Institutional, Research Grant: Akoya Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb , Eli Lilly and Company , Merck Sharp and Dohme, Navigate Biopharma, Pierre-Fabre, Ribon Therapeutics, Surface Oncology, Takeda Oncology, Tesaro, Inc.; Financial Interests, Advisory Board: EMD Serono, Shattuck Labs; Financial Interests, Research Grant: Moderna Inc. A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20